As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
16 Analysts have issued a Akero Therapeutics Inc forecast:
16 Analysts have issued a Akero Therapeutics Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -321 -321 |
37%
37%
|
|
| EBIT (Operating Income) EBIT | -321 -321 |
37%
37%
|
|
| Net Profit | -284 -284 |
39%
39%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Andrew Cheng |
| Employees | 63 |
| Founded | 2017 |
| Website | akerotx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


